Baxter International Inc (NYSE:BAX) Institutional Investor Positioning Change

September 30, 2018 - By Mark Babin

Baxter International Inc. (NYSE:BAX) Logo

Sentiment for Baxter International Inc (NYSE:BAX)

Baxter International Inc (NYSE:BAX) institutional sentiment increased to 0.88 in 2018 Q2. Its up 0.22, from 0.66 in 2018Q1. The ratio improved, as 325 institutional investors opened new or increased holdings, while 369 sold and reduced stakes in Baxter International Inc. The institutional investors in our partner’s database now have: 430.86 million shares, down from 432.17 million shares in 2018Q1. Also, the number of institutional investors holding Baxter International Inc in their top 10 holdings increased from 11 to 14 for an increase of 3. Sold All: 48 Reduced: 321 Increased: 230 New Position: 95.

Baxter International Inc. provides a portfolio of renal and hospital products. The company has market cap of $41.19 billion. The firm operates through two divisions, Hospital Products and Renal. It has a 46.95 P/E ratio. The Hospital Products segment makes intravenous solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products.

The stock increased 0.64% or $0.49 during the last trading session, reaching $77.09. About 3.48 million shares traded or 28.75% up from the average. Baxter International Inc. (NYSE:BAX) has risen 18.60% since September 30, 2017 and is uptrending. It has outperformed by 2.98% the S&P500.

Analysts await Baxter International Inc. (NYSE:BAX) to report earnings on October, 24. They expect $0.74 EPS, up 15.63 % or $0.10 from last year’s $0.64 per share. BAX’s profit will be $395.36M for 26.04 P/E if the $0.74 EPS becomes a reality. After $0.77 actual EPS reported by Baxter International Inc. for the previous quarter, Wall Street now forecasts -3.90 % negative EPS growth.

Third Point Llc holds 18.52% of its portfolio in Baxter International Inc. for 36.00 million shares. Sector Gamma As owns 721,058 shares or 8.85% of their US portfolio. Moreover, Suvretta Capital Management Llc has 5.38% invested in the company for 2.75 million shares. The United Kingdom-based Veritas Asset Management Llp has invested 5.37% in the stock. Healthcor Management L.P., a New York-based fund reported 1.80 million shares.

Since January 1, 0001, it had 0 insider purchases, and 8 sales for $16.14 million activity.

Baxter International Inc. (NYSE:BAX) Ratings Coverage

Ratings analysis reveals 57% of Baxter International’s analysts are positive. Out of 7 Wall Street analysts rating Baxter International, 4 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $72 while the high is $85. The stock’s average target of $79.33 is 2.91% above today’s ($77.09) share price. BAX was included in 8 notes of analysts from April 30, 2018. The stock of Baxter International Inc. (NYSE:BAX) has “Buy” rating given on Tuesday, May 22 by Bank of America. The firm has “Hold” rating given on Monday, April 30 by Stifel Nicolaus. JP Morgan maintained Baxter International Inc. (NYSE:BAX) on Friday, July 27 with “Overweight” rating. On Friday, July 27 the stock rating was maintained by PiperJaffray with “Overweight”. Piper Jaffray initiated the stock with “Buy” rating in Thursday, May 17 report. The stock of Baxter International Inc. (NYSE:BAX) earned “Neutral” rating by Citigroup on Monday, April 30. Citigroup maintained Baxter International Inc. (NYSE:BAX) rating on Tuesday, July 31. Citigroup has “Neutral” rating and $76 target.

Another recent and important Baxter International Inc. (NYSE:BAX) news was published by Seekingalpha.com which published an article titled: “Baxter collaborates with USC CBC to advance digital health solutions” on September 28, 2018.

Baxter International Inc. (NYSE:BAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: